Coronaviruses (CoVs) typically affect the respiratorytract of mammals, including humans, and lead to mild to severe respiratory tract infections1. In the past two decades, two highly pathogenic human CoVs (HCoVs).
Día: 28 de marzo de 2020
Profilaxis para Coronavirus (COVID-19) con Hidroxicloroquina/Cloroquina
La Hidroxicloroquina es un medicamento inmunomodulador utilizado por 60 años para el tratamiento de la malaria y enfermedades autoinmunes tales como lupus eritematoso sistémico y artritis inflamatoria.
Lopinavir/Ritonavir para el tratamiento de COVID-19
Lopinavir/ritonavir es una combinación fija de antivirales ampliamente utilizada para tratar la infección por VIH. En el marco de la pandemia por COVID-19 en 2019/2020, se ha sugerido que puede constituir un tratamiento para esta enfermedad.
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Hydroxychloroquine and azithromycin as a treatment of COVID-19
Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release.
Azithromycin induces anti-viral responses in bronchial epithelial cells
Respiratory viral infections are associated with the majority of asthma exacerbations (,80%) in both adults [1, 2] and children [3, 4]. Asthma exacerbations are the major cause of morbidity, mortality and healthcare costs in asthma [5].
Angiotensin‑converting enzyme 2 (ACE2) as a SARS‑CoV‑2 receptor: molecular mechanisms and potential therapeutic target
A novel infectious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China, in December 2019. The disease (COVID-19) spread rapidly, reaching epidemic proportions in China, and has been found in 27 other countries.
Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed.
¿Qué se sabe sobre ibuprofeno y otros antiinflamatorios no esteroideos (AINE) en relación con covid-19?
En los últimos días se ha difundido, tanto en los medios de comunicación como en las redes sociales, información que ponía en duda la seguridad del ibuprofeno con relación al tratamiento de los síntomas por la nueva enfermedad por el coronavirus (COVID-19). Desde la Red CIMLAC deseamos analizar brevemente los datos disponibles hasta el momento.